Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: A phase 3, open-label, randomised controlled, non-inferiority trial

The Lancet Infectious Diseases

Volumn 12, Issue 5, 2012, Pages 381-387

  Imamura, Hiroshi ^a   Kurokawa, Yukinori ^b   Tsujinaka, Toshimasa ^c   Inoue, Kentaro ^d   Kimura, Yutaka ^e   Iijima, Shohei ^f   Shimokawa, Toshio ^g   Furukawa, Hiroshi ^a  

^a SAKAI MUNICIPAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

^e OSAKA POLICE HOSPITAL   (Japan)

^f Minoh City Hospital   (Japan)

^g UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRONCHITIS; CANCER SURGERY; CONTROLLED STUDY; EXTENDED ANTIMICROBIAL PROPHYLAXIS; FEMALE; GASTRECTOMY; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTRAOPERATIVE ANTIMICROBIAL PROPHYLAXIS; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PEROPERATIVE CARE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; SURGICAL INFECTION; URINARY TRACT INFECTION; WOUND CLOSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURGICAL WOUND INFECTION;

EID: 84860313125     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70370-X     Document Type: Article

References (30)

1. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999, 20:250-278.
2. Hranjec T, Swenson BR, Sawyer RG Surgical site infection prevention: how we do it. Surg Infect 2010, 11:289-294.
3. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005, 140:174-182.
4. Sumiyama Y, Takesue Y Current status of prophylactic antibiotic therapy for prevention of postoperative infections after gastrointestinal surgery: a questionnaire covering 3,823 surgeons. Jpn J Chemotherapy 2004, 52:474-485. (in Japanese).
5. Utsumi M, Shimizu J, Miyamoto A, et al. Age as an independent risk factor for surgical site infections in a large gastrointestinal surgery cohort in Japan. J Hosp Infect 2010, 75:183-187.
6. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008, 359:453-462.
7. Imamura H, Furukawa H, Iijima S, et al. Multicenter phase II study of antimicrobial prophylaxis in low-risk patients undergoing distal gastrectomy for gastric cancer. Gastric Cancer 2006, 9:32-35.
8. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
9. Gastric cancer treatment guidelines 2004, Japanese Gastric Cancer Association, Kanehara, Tokyo, (in Japanese).
10. Japanese classification of gastric carcinoma-2nd English edition. Gastric Cancer 1998, 1:10-24. Japanese Gastric Cancer Association.
11. Onodera T, Goseki N, Kosaki G Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nippon Geka Gakkai Zasshi 1984, 85:1001-1005. (in Japanese).
12. Nichols RL Current strategies for prevention of surgical site infections. Curr Infect Dis Rep 2004, 6:426-434.
13. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006, 355:2640-2651.
14. Ahn HS, Yook JH, Park CH, et al. General perioperative management of gastric cancer patients at high-volume centers. Gastric Cancer 2011, 14:178-182.
15. Bratzler DW, Houck PM Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004, 38:1706-1715. for the Surgical Infection Prevention Guidelines Writers Workgroup.
16. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006, 7:309-315.
17. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:908-914.
18. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
19. Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v50-v54.
20. Guidelines for gastric cancer Ver 2 National Comprehensive Cancer Network, (accessed Jan 21, 2012). http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
21. Mohri Y, Tonouchi H, Kobayashi M, et al. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. Br J Surg 2007, 94:683-688.
22. Braga M, Baccari P, Di Palo S, et al. Effectiveness of perioperative short-term antibiotic prophylaxis in reducing surgical risk induced by malnutrition and anergy. Acta Chir Scand 1990, 156:751-757.
23. Imai E, Ueda M, Kanao K, et al. Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery. Am J Infect Control 2008, 36:727-731.
24. Suehiro T, Hirashita T, Araki S, et al. Prolonged antibiotic prophylaxis longer than 24 hours does not decrease surgical site infection after elective gastric and colorectal surgery. Hepatogastroenterology 2008, 55:1636-1639.
25. Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. Ann Surg 2004, 239:599-605.
26. Tsujinaka T, Sasako M, Yamamoto S, et al. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol 2007, 14:355-361.
27. Ozalp N, Zülfikaroĝlu B, Göçmen E, et al. Risk factors for surgical site infection after gastrectomy with D2 lymphadenectomy. Surg Today 2009, 39:1013-1015.
28. Malone DL, Genuit T, Tracy JK, et al. Surgical site infections: reanalysis of risk factors. J Surg Res 2002, 103:89-95.
29. Bernard AC, Davenport DL, Chang PK, et al. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg 2009, 208:931-937.
30. Gaynes RP, Culver DH, Horan TC, et al. Surgical site infection (SSI) rates in the United States, 1992-1998: the National Nosocomial Infections Surveillance System basic SSI risk index. Clin Infect Dis 2001, 33(suppl 2):S69-S77.